Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2012 | Ofatumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARZERRA (DIN 02381567) under ATC L01FA02 OFATUMUMAB. Indications are not published in the Drug Product Database — see… | DIN02381567 | withdrawnsource: Cancelled Post Marketsince Mar 1, 2019 | health-canada-dpd |
| Aug 13, 2012 | Ofatumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARZERRA (DIN 02381559) under ATC L01FA02 OFATUMUMAB. Indications are not published in the Drug Product Database — see… | DIN02381559 | withdrawnsource: Cancelled Post Marketsince Mar 1, 2019 | health-canada-dpd |
| Aug 9, 2012 | Triptorelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DECAPEPTYL (DIN 02389282) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database —… | DIN02389282 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 26, 2012 | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT EXEMESTANE (DIN 02390183) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product… | DIN02390183 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 11, 2012 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-LETROZOLE (DIN 02358514) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02358514 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 10, 2012 | Crizotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as XALKORI (DIN 02384264) under ATC L01ED01 CRIZOTINIB. Indications are not published in the Drug Product Database — see… | DIN02384264 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 10, 2012 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION, BP (DIN 02355183) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02355183 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 27, 2012 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN HYDROCHLORIDE FOR INJECTION (DIN 02379422) under ATC L01CE01 TOPOTECAN. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 23, 2012 | Vandetanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPRELSA (DIN 02378590) under ATC L01EX04 VANDETANIB. Indications are not published in the Drug Product Database —… | DIN02378590 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 23, 2011 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as AVA-BICALUTAMIDE (DIN 02360993) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02360993 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 4, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-LETROZOLE (DIN 02372282) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02372282 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP-LETROZOLE (DIN 02373009) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02373009 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2011 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02370034) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 28, 2011 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYTIGA (DIN 02371065) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product Database — see… | DIN02371065 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 27, 2011 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN HYDROCHLORIDE FOR INJECTION (DIN 02344009) under ATC L01CE01 TOPOTECAN. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 27, 2011 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE TRIHYDRATE FOR INJECTION (DIN 02345080) under ATC L01CE02 IRINOTECAN. Indications are not… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 11, 2011 | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE INJECTION (DIN 02351722) under ATC L01BB05 FLUDARABINE. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 29, 2011 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02360829) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02360829 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 22, 2011 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL FOR INJECTION USP (DIN 02320010) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 21, 2010 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP BICALUTAMIDE (DIN 02357216) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02357216 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 26, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ ANASTROZOLE (DIN 02338467) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02338467 | approvedsource: Marketed | health-canada-dpd |
| Jul 25, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02389851) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02389851 | approvedsource: Marketed | health-canada-dpd |
| Jul 25, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02389843) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02389843 | withdrawnsource: Cancelled Post Marketsince Feb 5, 2020 | health-canada-dpd |
| Jul 25, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02389835) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02389835 | approvedsource: Marketed | health-canada-dpd |
| Jul 25, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02389827) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02389827 | approvedsource: Marketed | health-canada-dpd |
| Jul 25, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02389819) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02389819 | approvedsource: Marketed | health-canada-dpd |
| Jul 19, 2012 | Ruxolitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAKAVI (DIN 02388022) under ATC L01EJ01 RUXOLITINIB. Indications are not published in the Drug Product Database — see… | DIN02388022 | approvedsource: Marketed | health-canada-dpd |
| Jul 19, 2012 | Ruxolitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAKAVI (DIN 02388014) under ATC L01EJ01 RUXOLITINIB. Indications are not published in the Drug Product Database — see… | DIN02388014 | approvedsource: Marketed | health-canada-dpd |
| Jul 19, 2012 | Ruxolitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAKAVI (DIN 02388006) under ATC L01EJ01 RUXOLITINIB. Indications are not published in the Drug Product Database — see… | DIN02388006 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 10, 2012 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as BICALUTAMIDE (DIN 02382423) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02382423 | withdrawnsource: Cancelled Post Marketsince Jan 22, 2020 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 10, 2012 | Crizotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as XALKORI (DIN 02384256) under ATC L01ED01 CRIZOTINIB. Indications are not published in the Drug Product Database — see… | DIN02384256 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 26, 2012 | Plerixafor | Health Canada CA | cancer not stated in this record | Marketed in Canada as MOZOBIL (DIN 02377225) under ATC L03AX16 PLERIXAFOR. Indications are not published in the Drug Product Database — see… | DIN02377225 | withdrawnsource: Cancelled Post Marketsince Oct 31, 2025 | health-canada-dpd |
| Mar 19, 2012 | Eribulin | Health Canada CA | cancer not stated in this record | Marketed in Canada as HALAVEN (DIN 02377438) under ATC L01XX41 ERIBULIN. Indications are not published in the Drug Product Database — see… | DIN02377438 | approvedsource: Marketed | health-canada-dpd |
| Mar 16, 2012 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN FOR INJECTION (DIN 02346656) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product… | DIN02346656 | withdrawnsource: Cancelled Post Marketsince Jul 20, 2021 | health-canada-dpd |
| Mar 8, 2012 | Ipilimumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as YERVOY (DIN 02379384) under ATC L01FX04 IPILIMUMAB. Indications are not published in the Drug Product Database — see… | DIN02379384 | approvedsource: Marketed | health-canada-dpd |
| Mar 5, 2012 | Vemurafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZELBORAF (DIN 02380242) under ATC L01EC01 VEMURAFENIB. Indications are not published in the Drug Product Database —… | DIN02380242 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 23, 2012 | Vandetanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPRELSA (DIN 02378582) under ATC L01EX04 VANDETANIB. Indications are not published in the Drug Product Database —… | DIN02378582 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 21, 2014 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Nov 22, 2022 |
| health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2026 |
| health-canada-dpd |
| Sep 30, 2011 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02327236) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02327236 | approvedsource: Marketed | health-canada-dpd |
| Sep 29, 2011 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION BP (DIN 02366711) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02366711 | withdrawnsource: Cancelled Post Marketsince Jul 25, 2022 | health-canada-dpd |
| Sep 8, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYL-LETROZOLE (DIN 02372169) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02372169 | withdrawnsource: Cancelled Post Marketsince Jun 28, 2016 | health-canada-dpd |
| Sep 2, 2011 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02360810) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02360810 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 28, 2025 |
| health-canada-dpd |
| Aug 31, 2011 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02324202) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02324202 | withdrawnsource: Cancelled Post Marketsince Jan 17, 2020 | health-canada-dpd |
| Aug 29, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02348896) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02348896 | withdrawnsource: Cancelled Post Marketsince Jun 25, 2014 | health-canada-dpd |
| Aug 23, 2011 | Cabazitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as JEVTANA (DIN 02369524) under ATC L01CD04 CABAZITAXEL. Indications are not published in the Drug Product Database —… | DIN02369524 | withdrawnsource: Cancelled Post Marketsince Dec 13, 2023 | health-canada-dpd |
| Aug 16, 2011 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371472) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published… | DIN02371472 | withdrawnsource: Cancelled Post Marketsince Sep 2, 2016 | health-canada-dpd |
| Aug 16, 2011 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371464) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published… | DIN02371464 | withdrawnsource: Cancelled Post Marketsince Sep 2, 2016 | health-canada-dpd |
| Aug 16, 2011 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371456) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published… | DIN02371456 | withdrawnsource: Cancelled Post Marketsince Jan 10, 2017 | health-canada-dpd |
| Aug 16, 2011 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371448) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published… | DIN02371448 | withdrawnsource: Cancelled Post Marketsince Jan 10, 2017 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 15, 2011 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TASIGNA (DIN 02368250) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see… | DIN02368250 | approvedsource: Marketed | health-canada-dpd |
| approved |
| health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2017 |
| health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2017 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 1, 2011 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOCETAXEL INJECTION USP (DIN 02361957) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02361957 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2017 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |